TransEnterix (NYSE:TRXC) shares jumped today after the medical device company said it sold its first Senhance robot-assisted surgery platform in the U.S., exactly a month after winning FDA clearance.
The sale, to Florida Hospital in Orlando, follows another sale in Taiwan made during the third quarter, president & CEO Todd Pope said during a conference call with analysts last week.